CHL [CHINA MOBILE] 6-K: (Original Filing)
[Number Page 1.1 Announcement, dated October 20, 2014 A-1 -2-]
CHL [CHINA MOBILE] 6-K: Number Page 1.1 Announcement, dated October 20, 2014
[Number Page 1.1 Announcement, dated October 20, 2014 A-1 -2-]
GOMO [Sungy Mobile] 6-K: (Original Filing)
[Sungy Mobile Limited Yuqiang Deng Chairman and Chief Executive Officer 2 Page 4 3 Sungy Mobile Announces Changes to the Board of Directors and the Executive Management Team Guangzhou, China, October 20, 2014 Sungy Mobile Limited (NASDAQ: GOMO), a leading provider of mobile internet products and services globally with a focus on applications and mobile platform development (Sungy Mobile]
GOMO [Sungy Mobile] 6-K: Sungy Mobile Limited Yuqiang Deng Chairman and Chief
[Sungy Mobile Limited Yuqiang Deng Chairman and Chief Executive Officer 2 Page 4 3 Sungy Mobile Announces Changes to the Board of Directors and the Executive Management Team Guangzhou, China, October 20, 2014 Sungy Mobile Limited (NASDAQ: GOMO), a leading provider of mobile internet products and services globally with a focus on applications and mobile platform development (Sungy Mobile]
FFHL [Fuwei Films] 6-K:
[] []
TPI [TIANYIN PHARMACEUTICAL] 8-K: (Original Filing)
[Tianyin Pharmaceutical Received Notices of Non-Compliance from NYSE MKT Tianyin Pharmaceutical Inc. (NYSE MKT: TPI, the “Company”), a pharmaceutical company that specializes in the development and sale of patented biopharmaceutical medicine, modernized traditional Chinese medicine (TCM), branded generics and active pharmaceutical ingredients (API), today reported that, on October 15, 2014, it received a notice from the NYSE MKT Staff indicating] []
TPI [TIANYIN PHARMACEUTICAL] 8-K: Tianyin Pharmaceutical Received Notices of Non-Compliance from NYSE
[Tianyin Pharmaceutical Received Notices of Non-Compliance from NYSE MKT Tianyin Pharmaceutical Inc. (NYSE MKT: TPI, the “Company”), a pharmaceutical company that specializes in the development and sale of patented biopharmaceutical medicine, modernized traditional Chinese medicine (TCM), branded generics and active pharmaceutical ingredients (API), today reported that, on October 15, 2014, it received a notice from the NYSE MKT Staff indicating] []
